Search results
Results From The WOW.Com Content Network
In January 2014, Bayer's CEO Marijn Dekkers allegedly stated that Nexavar was developed for "Western patients who can afford it, not for Indians". A kidney cancer patient would pay $96,000 (£58,000) for a year's course of the Bayer-made drug, whereas the cost of the Indian version of the generic drug would be around $2,800 (£1,700). [29]
In 2012, NATCO Pharma obtained compulsory license to produce a cheaper and generic version of Bayer's anti-cancer medication Nexavar. [ 7 ] In the United States, it launched influenza medication Tamiflu with marketing partner Alvogen , multiple sclerosis treatment drug glatiramer acetate in partnership with Mylan , and hepatitis C drugs under a ...
India succeeded in including a crucial clause to the agreement in the form of the right to grant compulsory licenses (CLs) to others to manufacture drugs in cases where the government felt that the patent holder was not serving the public health interest. This right was used in 2012, when Natco was granted a CL to produce Nexavar, a cancer drug ...
At a cost of $2,000.00 per injection, the cost to treat wet AMD patients in the United States is greater than $10.00 billion per year. Due to high cost, many ophthalmologists have turned to bevacizumab as the alternative intravitreal agent in the treatment of wet AMD.
Two Indian chemical companies have been indicted for allegedly importing ingredients for the highly addictive opioid fentanyl into the United States and Mexico, the U.S. Department of Justice said ...
The producer price index released a day earlier on January 14 reported a modest 0.3% increase in wholesale prices in December, rising 3.3% year over year, up from 3% in November.
What Makes Coligny Beach’s Water So Blue? The sand on Hilton Head Island is bright white, blissfully soft, and very fine, and the water is shallow, especially at low tide.
Sorafenib, co-developed and co-marketed with Bayer and sold under the trade name Nexavar, is a drug approved in the United States for the treatment of advanced renal cell carcinoma (kidney cancer) in 2005, and for the treatment of inoperable hepatocellular carcinoma, the most common form of liver cancer, in 2007.